Trattamento del Linfoma a Cellule B Diffuso Grande

Diffuse large B-cell lymphoma, the most common non-Hodgkin lymphoma subtype, represents 30% to 40% of cases globally. It is an aggressive but potentially curable malignant disease with substantial clinical and molecular heterogeneity. Gene expression profiling defines distinct molecular subtypes with differing prognostic and therapeutic implications. Frontline therapy typically involves anthracycline-based chemoimmunotherapy, most commonly rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Treatment strategies are tailored on the basis of disease stage, molecular subtype, patient fitness, and prognostic risk. Limited stage disease may be managed with abbreviated